It has been postulated that the aforementioned limitations will be greatly resolved by the use of a suitable delivery system of IL-2 to the tumor microenvironment to increase efficacy without causing systemic toxicity (Atkins et al. 1999; Davis and Gillies 2003). This evidence concerns the gene IL2 and neoplasm.